New developments in the management of moderate-to-severe hemophilia B

References

• SrivastavaABrewerAKMauser-BunschotenEPGuidelines for the management of hemophiliaHaemophilia2013191e1e4722776238
   PubMed Web of Science ®Google Scholar
• BowenDJHaemophilia A and haemophilia B: molecular insightsMol Pathol200255212714411950963
   PubMedGoogle Scholar
• GomezKKlamrothRMahlanguJMancusoMEMingotMEOzeloMCKey issues in inhibitor management in patients with haemophiliaBlood Transfus201412Suppl 1s319s32924333092
   PubMed Web of Science ®Google Scholar
• CollinsPWPalmerBPChalmersEAFactor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000–2011Blood2014124233389339725339360
   PubMed Web of Science ®Google Scholar
• WhiteGC2ndRosendaalFAledortLMLusherJMRothschildCIngerslevJDefinitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and HaemostasisThromb Haemost200185356011307831
   PubMed Web of Science ®Google Scholar
• AcharyaSSExploration of the pathogenesis of haemophilic joint arthropathy: understanding implications for optimal clinical managementBr J Haematol20121561132322050780
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMJUpdate on treatment regimens: prophylaxis versus on-demand therapySemin Hematol2003403 Suppl 33914690062
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMJAbshireTCShapiroADProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophiliaN Engl J Med2007357653554417687129
   PubMed Web of Science ®Google Scholar
• FurieBFurieBCMolecular and cellular biology of blood coagulationN Engl J Med1992326128008061538724
   PubMed Web of Science ®Google Scholar
• KaufmanRJPost-translational modifications required for coagulation factor secretion and functionThromb Haemost1998796106810799657426
   PubMed Web of Science ®Google Scholar
• MannKGBiochemistry and physiology of blood coagulationThromb Haemost199982216517410605701
   PubMed Web of Science ®Google Scholar
• HoffmanMMonroeDMOliverJARobertsHRFactors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulationBlood1995865179418017655009
   PubMed Web of Science ®Google Scholar
• RandMDLockJBvan’t VeerCGaffneyDPMannKGBlood clotting in minimally altered whole bloodBlood1996889343234458896408
   PubMed Web of Science ®Google Scholar
• BjörkmanSBerntorpEPharmacokinetics of coagulation factors: clinical relevance for patients with haemophiliaClin Pharmacokinet2001401181583211735604
   PubMed Web of Science ®Google Scholar
• BjörkmanSCarlssonMBerntorpEPharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretationEur J Clin Pharmacol19944643253327957517
   PubMed Web of Science ®Google Scholar
• BrietEThree Problems of Hemophilia BLeiden, The NetherlandsUniversity of Leiden1977
   Google Scholar
• UprichardJAdamidouDGoddardNJMannHAYeeTTFactor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000–2010Haemophilia2012181464921545378
   PubMed Web of Science ®Google Scholar
• SternDMKnitterGKisielWNawrothPPIn vivo evidence of intravascular binding sites for coagulation factor IXBr J Haematol19876622272323496917
   PubMed Web of Science ®Google Scholar
• FengDStaffordKABrozeGJStaffordDWEvidence of clinically significant extravascular stores of factor IXJ Thromb Haemost201311122176217824112220
   PubMed Web of Science ®Google Scholar
• CheungWFvan den BornJKühnKKjellénLHudsonBGStaffordDWIdentification of the endothelial cell binding site for factor IXProc Natl Acad Sci U S A1996932011068110738855310
   PubMed Web of Science ®Google Scholar
• GuiTLinHFJinDYCirculating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivoBlood2002100115315812070021
   PubMed Web of Science ®Google Scholar
• BajajSPRapaportSIProdanosCA simplified procedure for purification of human prothrombin, factor IX and factor XPrep Biochem19811143974127312833
   PubMed Web of Science ®Google Scholar
• GuiTRehemanANiHAbnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IVJ Thromb Haemost20097111843185119583826
   PubMed Web of Science ®Google Scholar
• WhiteGShapiroARagniMClinical evaluation of recombinant factor IXSemin Hematol1998352 Suppl 233389565165
   PubMed Web of Science ®Google Scholar
• WhiteGC2ndShapiroADKurczynskiEMKimHCBergmanGEVariability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study GroupThromb Haemost19957357797847482403
   PubMed Web of Science ®Google Scholar
• EwensteinBMJoistJHShapiroADPharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia BTransfusion200242219019711896334
   PubMed Web of Science ®Google Scholar
• PoonMCLillicrapDHensmanCCardRScullyMFRecombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance studyThromb Haemost200287343143511916075
   PubMed Web of Science ®Google Scholar
• PetersRTLowSCKamphausGDProlonged activity of factor IX as a monomeric Fc fusion proteinBlood2010115102057206420056791
   PubMed Web of Science ®Google Scholar
• ArrudaVRHagstromJNDeitchJPosttranslational modifications of recombinant myotube-synthesized human factor IXBlood200197113013811133752
   PubMed Web of Science ®Google Scholar
• GilGCVelanderWHVan CottKEAnalysis of the N-glycans of recombinant human factor IX purified from transgenic pig milkGlycobiology200818752653918456721
   PubMed Web of Science ®Google Scholar
• WhiteGC2ndBeebeANielsenBRecombinant factor IXThromb Haemost19977812612659198163
   PubMed Web of Science ®Google Scholar
• MenacheDProthrombin complex concentrates: clinical useAnn N Y Acad Sci19813707477566791551
   PubMedGoogle Scholar
• EvattBLThe tragic history of AIDS in the hemophilia population, 1982–1984J Thromb Haemost20064112295230116972935
   PubMed Web of Science ®Google Scholar
• MannucciPMClinical evaluation of viral safety of coagulation factor VIII and IX concentratesVox Sang19936441972038517048
   PubMed Web of Science ®Google Scholar
• KeyNSNegrierCCoagulation factor concentrates: past, present, and futureLancet2007370958543944817679021
   PubMed Web of Science ®Google Scholar
• LimentaniSAGowellKPDeitcherSRHigh-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potentialActa Haematol199594Suppl 112177571989
   PubMed Web of Science ®Google Scholar
• PipeSWRecombinant clotting factorsThromb Haemost200899584085018449413
   PubMed Web of Science ®Google Scholar
• NilssonIMBerntorpELöfqvistTPetterssonHTwenty-five years’ experience of prophylactic treatment in severe haemophilia A and BJ Intern Med1992232125321640190
   PubMed Web of Science ®Google Scholar
• WitmerCPresleyRKulkarniRSoucieJMMannoCSRaffiniLAssociations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United StatesBr J Haematol2011152221121621114482
   PubMed Web of Science ®Google Scholar
• OladapoAOEpsteinJDWilliamsEItoDGringeriAValentinoLAHealth-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trialsHaemophilia201521e344e35826390060
   PubMed Web of Science ®Google Scholar
• CoppolaATagliaferriADi CapuaMFranchiniMProphylaxis in children with hemophilia: evidence-based achievements, old and new challengesSemin Thromb Hemost2012381799422314606
   PubMed Web of Science ®Google Scholar
• BerntorpEJoint outcomes in patients with haemophilia: the importance of adherence to preventive regimensHaemophilia20091561219122719659939
   PubMed Web of Science ®Google Scholar
• ChandyMManagement of hemophilia with minimal factor replacement in developing countries: role of ancillary therapySemin Thromb Hemost200531550150616276457
   PubMed Web of Science ®Google Scholar
• KimHCMcMillanCWWhiteGCBergmanGEHortonMWSaidiPPurified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentratesBlood19927935685751531035
   PubMed Web of Science ®Google Scholar
• HamptonKKPrestonFELoweGDWalkerIDSampsonBReduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrateBr J Haematol19938422792848398831
   PubMed Web of Science ®Google Scholar
• TaborEThe epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1Transfusion19993911–121160116810604241
   PubMed Web of Science ®Google Scholar
• BrownPWillRGBradleyRAsherDMDetwilerLBovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concernsEmerg Infect Dis20017161611266289
   PubMed Web of Science ®Google Scholar
• Bartolomei CorsiOAzziAMorfiniMFanciRRossi FerriniPHuman parvovirus infection in haemophiliacs first infused with treated clotting factor concentratesJ Med Virol19882521651702839609
   PubMed Web of Science ®Google Scholar
• MannucciPMThe safety of plasma-derived versus recombinant concentratesOccasional Papers2004514
   Google Scholar
• LissitchkovTMatysiakMZavilskaKA clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine®, a high-purity factor IX concentrate, in patients with severe haemophilia BHaemophilia201117459059621299747
   PubMed Web of Science ®Google Scholar
• WhiteGC2ndSafety and recovery of Mononine in multiple-dose, high-dose regimensActa Haematol199594Suppl 15357 discussion 57–587571996
   PubMed Web of Science ®Google Scholar
• MénartCPetitPYAttaliOMassignonDDechavanneMNégrierCEfficacy and safety of continuous infusion of Mononine during five surgical procedures in three hemophilic patientsAm J Hematol19985821101169625577
   PubMed Web of Science ®Google Scholar
• HootsWKLeissingerCStablerSContinuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia BHaemophilia20039216417212614367
   PubMed Web of Science ®Google Scholar
• AlameluJBevanDSorensenBRangarajanSPharmacokinetic and pharmacodynamic properties of plasma-derived vs recombinant factor IX in patients with hemophilia B: a prospective crossover studyJ Thromb Haemost201412122044204825315324
   PubMed Web of Science ®Google Scholar
• Mauser-BunschotenEPKleine BuddeILopaciukSAn ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact(R)), results of phase III and IV clinical studiesHaemophilia201117343944521362109
   PubMed Web of Science ®Google Scholar
• BjörkmanSAhlénVPopulation pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxisEur J Clin Pharmacol201268696997722281721
   PubMed Web of Science ®Google Scholar
• National Hemophilia Foundation no. 179MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding)2007
   Google Scholar
• ChooKHGouldKGReesDJBrownleeGGMolecular cloning of the gene for human anti-haemophilic factor IXNature198229958791781806287289
   PubMed Web of Science ®Google Scholar
• KaufmanRJWasleyLCFurieBCFurieBShoemakerCBExpression, purification, and characterization of recombinant gamma-carboxylated factor IX synthesized in Chinese hamster ovary cellsJ Biol Chem198626121962296283733688
   PubMed Web of Science ®Google Scholar
• RothDAKesslerCMPasiKJHuman recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentratesBlood200198133600360611739163
   PubMed Web of Science ®Google Scholar
• ShapiroADDi PaolaJCohenAThe safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia BBlood2005105251852515383463
   PubMed Web of Science ®Google Scholar
• PolackBCalvezTChambostHEQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in FranceTransfusion20155571787179725652955
   PubMed Web of Science ®Google Scholar
• KontermannREStrategies for extended serum half-life of protein therapeuticsCurr Opin Biotechnol201122686887621862310
   PubMed Web of Science ®Google Scholar
• ShapiroADRagniMVValentinoLARecombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsBlood2012119366667222110246
   PubMed Web of Science ®Google Scholar
• PowellJSPasiKJRagniMVPhase 3 study of recombinant factor IX Fc fusion protein in hemophilia BN Engl J Med2013369242313232324304002
   PubMed Web of Science ®Google Scholar
• PowellJShapiroARagniMSwitching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding ratesBr J Haematol2015168111312325209873
   PubMed Web of Science ®Google Scholar
• ChaudhuryCBrooksCLCarterDCRobinsonJMAndersonCLAlbumin binding to FcRn: distinct from the FcRn-IgG interactionBiochemistry200645154983499016605266
   PubMed Web of Science ®Google Scholar
• MetznerHJWeimerTKronthalerULangWSchulteSGenetic fusion to albumin improves the pharmacokinetic properties of factor IXThromb Haemost2009102463464419806248
   PubMed Web of Science ®Google Scholar
• NolteMWNicholsTCMueller-CohrsJImproved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogsJ Thromb Haemost20121081591159922726310
   PubMed Web of Science ®Google Scholar
• SantagostinoEPROLONG-9FP clinical development program – phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP)Thromb Res2013131Suppl 2S7S1023537724
   PubMed Web of Science ®Google Scholar
• MartinowitzULissitchkovTLubetskyAResults of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patientsHaemophilia201521678479025990590
   PubMed Web of Science ®Google Scholar
• KenetGChambostHMaleCEfficacy, pharmacokinetics (PK) and safety results of a phase 3 clinical study of recombinant fusion protein linking coagulation factor IX with albumin (RIX-FP) in previously treated children with hemophilia BPaper presented at: International Society of Thrombosis and Haemostasis Meeting, 2015Toronto, Canada
   Google Scholar
• SantagostinoEMartinowitzULissitchkovTEfficacy and safety results of a phase 3 pivotal clinical study of recombinant fusion protein linking coagulation factor IX with albumin (RIX-FP) in previously treated patients with hemophilia BPaper presented at: International Society of Thrombosis and Haemostasis Meeting2015Toronto, Canada
   Google Scholar
• NegrierCLepatanLMLubetskyAEfficacy and safety of recombinant fusion protein linking coagulation factor IX with albumin (RIX-FP) in previously treated patients with hemophilia B undergoing a surgical procedurePaper presented at: International Society of Thrombosis and Haemostasis MeetingJune 20–25, 2015Toronto, Canada
   Google Scholar
• CalicetiPVeroneseFMPharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugatesAdv Drug Deliv Rev200355101261127714499706
   PubMed Web of Science ®Google Scholar
• ØstergaardHBjelkeJRHansenLProlonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptideBlood201111882333234121700771
   PubMed Web of Science ®Google Scholar
• NegrierCKnobeKTiedeAGiangrandePMøssJEnhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia BBlood2011118102695270121555744
   PubMed Web of Science ®Google Scholar
• CollinsPWYoungGKnobeKRecombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialBlood2014124263880388625261199
   PubMed Web of Science ®Google Scholar
• KaoCYYangSJTaoMHJengYMYuISLinSWIncorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivoThromb Haemost2013110224425623676890
   PubMed Web of Science ®Google Scholar
• BrooksARSimDGritzanUGlycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacyJ Thromb Haemost20131191699170623692404
   PubMed Web of Science ®Google Scholar
• WestmarkPRTanratanaPSheehanJPSelective disruption of heparin and antithrombin-mediated regulation of human factor IXJ Thromb Haemost20151361053106325851619
   PubMed Web of Science ®Google Scholar
• SainiSHamasaki-KatagiriNPandeyGSGenetic determinants of immunogenicity to factor IX during the treatment of haemophilia BHaemophilia201521221021825470321
   PubMed Web of Science ®Google Scholar
• PuetzJSoucieJMKemptonCLMonahanPEHemophilia Treatment Center NetworkIPrevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection databaseHaemophilia2014201253123855900
   PubMed Web of Science ®Google Scholar
• KatzJPrevalence of FIX Inhibitors among patients with hemophilia B: results of large scale North America surveyHaemophilia199622831
   PubMed Web of Science ®Google Scholar
• DiMicheleDInhibitor development in haemophilia B: an orphan disease in need of attentionBr J Haematol2007138330531517614818
   PubMed Web of Science ®Google Scholar
• WarrierIEwensteinBMKoerperMAFactor IX inhibitors and anaphylaxis in hemophilia BJ Pediatr Hematol Oncol199719123279065715
   PubMed Web of Science ®Google Scholar
• EhrenforthSKreuzWScharrerIIncidence of development of factor VIII and factor IX inhibitors in haemophiliacsLancet199233987935945981347102
   PubMed Web of Science ®Google Scholar
• RechtMPollmannHTagliaferriAMussoRJancoRNeumanWRA retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia BHaemophilia201117349449921518148
   PubMed Web of Science ®Google Scholar
• SiboniSMMannucciPMGringeriAHealth status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapyJ Thromb Haemost20097578078619220727
   PubMed Web of Science ®Google Scholar
• WebsterRDidierEHarrisPPEGylated proteins: evaluation of their safety in the absence of definitive metabolism studiesDrug Metab Dispos200735191617020954
   PubMed Web of Science ®Google Scholar
• HerzogEHarrisSHensonCBiodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in ratsThromb Res2014133590090724680550
   PubMed Web of Science ®Google Scholar
• GaterAThomsonTAStrandberg-LarsenMHaemophilia B: impact on patients and economic burden of diseaseThromb Haemost2011106339840421833450
   PubMed Web of Science ®Google Scholar
• HildenILauritzenBSørensenBBHemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia modelBlood2012119245871587822563084
   PubMed Web of Science ®Google Scholar
• ChowdaryPLethagenSFriedrichUSafety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trialJ Thromb Haemost201513574375425641556
   PubMed Web of Science ®Google Scholar
• SehgalABarrosSIvanciuLAn RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophiliaNat Med201521549249725849132
   PubMed Web of Science ®Google Scholar
• PasiKJGeorgievPMantTA subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim weekly and monthly dosing results in patients with hemophilia A or BBlood2015126551
   Web of Science ®Google Scholar